• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus.
Abstract Oral anticoagulants (OAC) are widely used for prevention of systemic thromboembolism, including the reduction of the risk of stroke in patients with atrial fibrillation (AF) and prosthetic heart valves. There is also an increasing population of patients who require not only OACs, but also double antiplatelet therapy (DAPT). A typical example is a patient with AF and stable coronary artery disease or acute coronary syndrome (ACS), treated by percutaneous coronary intervention (PCI). In recent years, with the introduction of NOACs, triple or dual therapy has become safer. Regardless of these indications for...
Source: Polish Heart Journal - February 25, 2019 Category: Cardiology Authors: Witkowski A, Barylski M, Filipiak KJ, Gierlotka M, Legutko J, Lesiak M, Stępińska J, Wojakowski W Tags: Kardiol Pol Source Type: research

New oral anticoagulants in the prevention of thromboembolic complications in atrial fibrillation - a single-center experience.
Abstract Introduction:The prevention of thromboembolic complications in patients with atrial fibrillation(AF) takes priority in this group. In light of applicable guidelines, thesignificance of vitamin K antagonists (VKA) in stroke prevention decreased in favorofan ever more important role of new oral anticoagulants (nOAC). Theobjectives of this study are: theevaluation of the frequency of nOAC recommendations, the comparison between thepopulation of patients treatedwith VKA and those receiving nOAC, as well as theidentification of factors predisposing to the administration of nOAC to AF patients ondischarge.Metho...
Source: Polish Heart Journal - September 2, 2014 Category: Cardiology Authors: Gorczyca-Michta I, Wożakowska-Kapłon B Tags: Kardiol Pol Source Type: research